Ghassan Abou-Alfa, Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Incredible finale of 80802 1st Alliance for Clinical Trials in Oncology HCC study led by Memorial Sloan Kettering Cancer Center Department of Medicine with radiomic signatures to estimate survival.
Congratulations Larry Schwartz, Laurent Dercle! Stay tuned with more AI efforts coming!”
Title: Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)
Authors: L. Dercle, S. Geyer, A.B. Nixon, F. Innocenti, Q. Shi, S.B. Jacobson, L. Luk, A. Liu, H. Yang, Y. Wen, B. Zhao, T. Eche, F.-Z. Mokrane, M. Yang, J. Meyerhardt, E.M. O’Reilly, A.P. Venook, A.B. El-Khoueiry, L.H. Schwartz, G.K. Abou-Alfa
Read the Full Article on ESMO Open
More post featuring Ghassan Abou-Alfa.